Analyst firms · H.C. Wainwright · CHRS

H.C. Wainwright CHRS price target and rating history

Coherus Oncology Inc. (CHRS) · Health Care

H.C. Wainwright rates Coherus Oncology Inc. (CHRS) Buy with a $7 price target, as of its latest action on Oct 29, 2026. It has published 3 rating actions on CHRS since July 2021, including 0 upgrades and 0 downgrades. Across 3 firms with a CHRS price target in the last 12 months, the median target is $10. H.C. Wainwright's $7 is 30% below that.

Current rating
Buy
Price target
$7
Median target, all firms
$10
Actions on CHRS
3

H.C. Wainwright price target on CHRS

$36$22$720222023202420252026
H.C. Wainwright price target on CHRS, each point a stated target, July 2021 to October 2026.

Every H.C. Wainwright rating on CHRS

How other firms rate CHRS

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
H.C. WainwrightBuy$7Oct 29, 2026
GuggenheimBuy$12May 11, 2026
OppenheimerOutperform$10Jan 23, 2026

Questions about H.C. Wainwright and CHRS

What is H.C. Wainwright's price target for CHRS?
H.C. Wainwright's latest stated price target for Coherus Oncology Inc. (CHRS) is $7, from its action on Oct 29, 2026.
What is H.C. Wainwright's rating on CHRS?
H.C. Wainwright rates CHRS Buy, a bullish rating, as of Oct 29, 2026.
When did H.C. Wainwright last change its view on CHRS?
On Oct 29, 2026, H.C. Wainwright resumes coverage at Buy, price target $7.
How does H.C. Wainwright's CHRS target compare with other analysts?
Across 3 firms with a CHRS price target in the last 12 months, the median target is $10. H.C. Wainwright's $7 is 30% below that.

More CHRS rating histories

All H.C. Wainwright ratingsCHRS news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.